Trial Update: Phase 3 Study Involving Desmopressin Now Active, Not Recruiting

On October 7, 2026, a Phase 3 clinical trial titled "Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children" was listed as active, not recruiting. The trial, registered under identifier NCT07398261, is studying treatment approaches for non-monosymptomatic nocturnal enuresis in pediatric patients. Desmopressin, an approved medication, is relevant to this condition area. The study's current status indicates that participant enrollment has concluded and the trial is proceeding through its active phase. No results have been posted for this trial at this time. The trial is registered as Phase 3, reflecting a later stage of clinical investigation. This update reflects only the current status of the trial as recorded, without indication of outcomes or findings. Readers should note that status changes in clinical trials, such as moving from recruiting to active and not recruiting, are standard progression steps in the research process. For more background on desmopressin, including its approved uses, readers can consult the compound overview.